Wrap Text
Revised 2020 full-year results date
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)
13 May 2020
REVISED 2020 FULL-YEAR RESULTS DATE
Mediclinic announces a revised date for the publication of its preliminary results for the year
ended 31 March 2020. Following recent guidance from the Financial Conduct Authority and
Financial Reporting Council on corporate reporting timetables in light of COVID-19, results will
be published on 2 June 2020, rather than 21 May 2020 as previously indicated. This allows the
Company and its auditors, PricewaterhouseCoopers, sufficient time to complete the preparation
and review of results, given the practical challenges of remote working.
As usual, the Group will host an audio webcast presentation and Q&A session on the morning
of the release of the results, details of which will be available in advance on the ‘Investor
relations’ section of the Company’s website.
The Company anticipates its 2020 Annual General Meeting (“AGM”) to continue on 22 July
2020. Further details of the AGM arrangements will be published alongside the Group’s 2020
Annual Report and Financial Statements.
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United
Arab Emirates (“UAE”).
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
At 31 March 2020, Mediclinic comprised 77 hospitals, six sub-acute hospitals, 14 day case
clinics and 21 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics and
three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern
Africa operations included 53 hospitals (three of which in Namibia), six sub-acute hospitals and
10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8
500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics
and 18 outpatient clinics with more than 900 inpatient beds in the UAE.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United
Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock
Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 13-05-2020 08:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
